REGN vs GILD
REGN and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | REGNREGENERON PHARMACEUTICALS, INC. | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | — | $216.95B |
| P/E (TTM) | 20.8 | 25.8 |
| P/B | — | 16.64 |
| P/S | — | 7.4x |
| Dividend yield | — | 1.85% |
| Revenue | $16.90B(TTM) | $30.99B(TTM) |
| Revenue growth (YoY) | 1.0% | 2.4% |
| Net income | $4.82B(TTM) | -$3.86B(TTM) |
| Earnings growth (YoY) | 2.1% | 1672.9% |
| EPS, diluted | $45.24(TTM) | $-3.13(TTM) |
| EBIT margin | 24.9% | 34.0% |
| ROE | 13.4% | 65.3% |
| ROIC | 9.2% | 25.7% |
| 1y total return | +50.0% | +44.6% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: REGN frente a GILD
| Métrica | REGN | GILD |
|---|---|---|
| Valor final | $26.4K | $29.9K |
| Retorno total | +163.8% | +198.8% |
| CAGR | +9.8% | +11.2% |
| Volatilidad | 32.3% | 25.6% |
| Sharpe | 0.32 | 0.38 |
| Sortino | 0.48 | 0.56 |
| Caída máxima | -59.7% | -30.5% |
Basado en 2600 días de negociación comunes, 2016-07-05 → 2026-11-04 · tasa libre de riesgo 4.21% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)